Kuznik. B I BI; Khasanova. N B NB; Ryzhak. G A GA; Mezsheriakova. I E IE; Khavinson. V K VK
The paper reviews animal and cell‑culture studies showing that a liver‑derived polypeptide mix (Ventvil) and a short peptide called KEDA (Livagen) can protect the liver, boost immune function, and reduce age‑related liver damage. The results are promising but come from pre‑clinical models, not human trials.
Khavinson. V Kh VKh; Lezhava. T A TA; Monaselidze. J G JG; Dzhokhadze. T A TA; Dvalishvili. N A NA;...
The study found that the synthetic peptide Livagen can change the way DNA is packaged in white blood cells from older people, making certain genes more active. It seems to loosen tightly packed DNA regions and turn on genes that usually get turned off with age, which could be linked to healthier cells.
Timofeeva. N M NM; Khavinson. V Kh VKh; Malinin. V V VV; Nikitina. A A AA; Egorova. V V VV
Livagen is a short peptide that isn’t broken down much by the gut. In lab tests it cuts the activity of one gut enzyme by half. When given to rats for two weeks, it lowered digestive enzyme activity in young rats but boosted it in older rats, bringing the older rats’ enzyme levels close to those of young healthy rats. The study is in animals only, so it’s not a ready‑to‑use protocol for people.
Dzhokhadze. T A TA; Ganozishvili. M N MN; Lezhava. T A TA
The study looked at how heavy metals and two peptide supplements (Livagen and Epithalon) affect tiny breaks in chromosomes called fragile sites. Young people showed more natural fragile sites than older adults, and heavy metals made these breaks worse. Livagen (and Epithalon) helped lower the metal‑induced damage, but only in the young group, and the research was small and didn’t give dosing details.
Dzhokhadze. T A TA; Buadze. T Zh TZh; Gaiozishvili. M N MN; Kakauridze. N G NG; Lezhava. T A TA
The study found that people with atherosclerosis have more chromosome damage in their blood cells, and that a short peptide called Livagen (Lys‑Glu‑Asp‑Ala), especially when paired with cobalt ions, helped bring those damage markers back toward normal in lab cultures.
The study shows that in cells taken from very old people, the DNA becomes more tightly packed (heterochromatin) with age, which can silence genes. Adding the peptide Livagen in the lab helped loosen this packing and reduced DNA damage caused by cobalt ions. However, the work was done only in cultured lymphocytes, not in living humans.
Dzhokhadze. T A TA; Buadze. T Zh TZh; Dvalishvili. N A NA; Lezhava. T A TA
A lab study found that blood cells from older people still react to low‑dose radiation, and a peptide called Livagen seemed to help fix stress responses in those cells, but the work was done in test tubes and didn’t give any real‑world dosing or usage advice.
Jokhadze. T T; Gaiozishvili. M M; Buadze. T T; Sigua. T T; Namchelvadze. E E; Lezhava. T T
The study looked at blood cells from women with ductal breast cancer and found they had lots of DNA damage and chromosome problems. When those cells were treated in the lab with the peptide Livagen and cobalt ions, the damage decreased, suggesting a protective effect in this test setting.
A lab study found that a short peptide called Livagen, especially when mixed with cobalt ions, changes certain chromosome structures in white blood cells taken from people with hypertrophic cardiomyopathy and their family members. The changes suggest the cells' DNA becomes less tightly packed, which the authors think might be protective, but no actual health benefits were measured in people.
Riadnova. I Iu IIu; Filippov. S V SV; Iuzhakov. V V VV
The researchers tested a tiny protein called livagen on liver cells grown in a lab dish and found it helped keep the cells stable and supported their ability to regenerate, but the work was only done in vitro and no human data or dosing guidance were provided.